New drug to reverse Alzheimer's
(trial involves 360 people)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
Early trials of Kiovig have shown that the new treatment had a significant stabilising effect on people with the degenerative disease – halting the shrinkage of the brain and maintaining memory and speed of thought.
Now Weill Cornell Medical Center in New York and the drug company Baxter International have launched a much larger trial to confirm the early results. Dr Norbert Riedel, chief scientific officer of the company, said that the early results had been "striking". Kiovig, or Gammagard as it is known in the US, is the brand name of an immunotherapy product already used for the treatment of a variety of immune disorders.
The product, which is really a mix of antibodies derived from human blood, is known generically as immune globulin and is applied intravenously once a fortnight. It contains antibodies against a protein called beta-amyloid, which many Alzheimer’s researchers believe plays a pivotal role in the progression of the disease. Plaques of beta-amyloids are thought to "silt up" the brain and cause nerve death and loss of function. One of the early trials, published in the journal Neurology, found that the drug reduced the progression of Alzheimer's by as much as 42 per cent. Read more: telegraph.co.uk
Olive oil protects from liver damage
Olive oil compounds may protect against oxidative stress in the liver, according to a new study in rats. Read more: nutraingredients.com
No comments:
Post a Comment